GAM Holding AG grew its holdings in Edwards Lifesciences Corp (NYSE:EW) by 3.3% during the 3rd quarter, Holdings Channel reports. The firm owned 25,506 shares of the medical research company’s stock after purchasing an additional 806 shares during the period. GAM Holding AG’s holdings in Edwards Lifesciences were worth $4,441,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC boosted its stake in shares of Edwards Lifesciences by 32.9% in the 2nd quarter. FMR LLC now owns 6,714,684 shares of the medical research company’s stock valued at $977,456,000 after purchasing an additional 1,663,511 shares during the last quarter. Brown Advisory Inc. raised its position in shares of Edwards Lifesciences by 2.2% in the 3rd quarter. Brown Advisory Inc. now owns 3,950,371 shares of the medical research company’s stock valued at $687,760,000 after acquiring an additional 84,355 shares during the period. Janus Henderson Group PLC raised its position in shares of Edwards Lifesciences by 117.0% in the 3rd quarter. Janus Henderson Group PLC now owns 2,505,128 shares of the medical research company’s stock valued at $436,144,000 after acquiring an additional 1,350,879 shares during the period. Jennison Associates LLC raised its position in shares of Edwards Lifesciences by 70.8% in the 3rd quarter. Jennison Associates LLC now owns 1,444,384 shares of the medical research company’s stock valued at $251,467,000 after acquiring an additional 598,735 shares during the period. Finally, Morgan Stanley raised its position in shares of Edwards Lifesciences by 38.4% in the 2nd quarter. Morgan Stanley now owns 1,329,458 shares of the medical research company’s stock valued at $193,531,000 after acquiring an additional 369,027 shares during the period. 82.55% of the stock is currently owned by institutional investors.
A number of analysts recently weighed in on the stock. Cowen set a $190.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Friday. UBS Group assumed coverage on shares of Edwards Lifesciences in a research report on Tuesday, November 27th. They issued a “neutral” rating and a $165.00 price target on the stock. Citigroup cut their price target on shares of Edwards Lifesciences from $121.00 to $118.00 and set a “sell” rating on the stock in a research report on Monday, October 29th. Zacks Investment Research downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, October 25th. Finally, Barclays set a $143.00 price target on shares of Edwards Lifesciences and gave the company a “sell” rating in a research report on Wednesday, October 24th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. Edwards Lifesciences presently has a consensus rating of “Buy” and a consensus target price of $158.45.
Shares of EW stock opened at $162.01 on Monday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.31. The company has a market cap of $33.87 billion, a price-to-earnings ratio of 42.63, a P/E/G ratio of 2.13 and a beta of 0.90. Edwards Lifesciences Corp has a 52 week low of $110.68 and a 52 week high of $175.00.
Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, October 23rd. The medical research company reported $1.07 EPS for the quarter, topping the consensus estimate of $1.02 by $0.05. The firm had revenue of $906.60 million for the quarter, compared to the consensus estimate of $927.56 million. Edwards Lifesciences had a net margin of 20.67% and a return on equity of 30.11%. The business’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the company posted $0.84 EPS. On average, analysts forecast that Edwards Lifesciences Corp will post 4.7 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “GAM Holding AG Acquires 806 Shares of Edwards Lifesciences Corp (EW)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.com-unik.info/2018/12/03/gam-holding-ag-acquires-806-shares-of-edwards-lifesciences-corp-ew.html.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Featured Story: What are the reasons investors use put options?
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.